Over the last few years, scientists have discovered connections between gut microbiota imbalances and various diseases. Now, in a study using mice, biologists from the CNRS, INSERM, and Claude Bernard Lyon 1 University—together with colleagues from the Institut Pasteur de Lille and the NIH (USA)—have revealed a surprising relationship between a viral detection system, the composition of the gut microbiota, and the development of skin allergies. Their findings, published in PNAS (September 24, 2018) suggest potential new therapies.
The number of microorganisms hosted in our digestive tracts is 10 to 100 times greater than that of all the cells that make up our bodies, and the delicately balanced ecosystem they constitute may be modified by our diet and medication. Epidemiological data of various kinds suggest a link between changes in gut microbiota composition and the development of allergic diseases, like eczema, at body sites far removed from the intestine. But an explanation for this association had been lacking until now.
At the International Center for Infectiology Research (CNRS / INSERM / Claude Bernard Lyon 1 University / ENS de Lyon)—or CIRI—a team led by two researchers from the CNRS focused their attention on mice deprived of the MAVS gene, which plays a key role in the detection of viruses by the immune system. They noted an altered gut microbiota and severe allergic skin reactions in these mice. To demonstrate a relationship between the two phenomena, the researchers transferred the altered microbiota to normal mice. The latter in turn developed severe allergic reactions, showing that the transplanted gut bacteria were responsible.
These findings shed light on the unexpected role played by an antiviral protein (MAVS) in the maintenance of gut microbiota equilibrium. By showing that changes in the gut microbiota exacerbate the allergic response in the skin, this research sets the stage for the development of new therapies. In the not so distant future, might we treat eczema, or enhance already existing treatments, by acting on the microbiota? This approach is already being investigated for other diseases, like cancer.
Researchers are now able to edit the genome with precision using the "gene editing scissors" of CRISPR-Cas9, which is a highly promising tool for gene therapy. The technical challenge now is to get this tool into the genome of certain cells. With ...
In a paper published in the journal Science Translational Medicine , Guy and his team Gorochov research center CIMI (Inserm / Université Sorbonne) and Immunology Department at the Pitié-Salpêtrière Hospital, AP-HP, reveal that our IgA act as conductor of the intestinal microbiota. ...
MAVS deficiency induces gut dysbiotic microbiota conferring a pro-allergic phenotype Emilie Plantamura, Amiran Dzutsev, Mathias Chamaillard, Sophia Djebali, Lyvia Moudombi, Lilia Boucinha, Morgan Grau, Claire Macari, David Bauche, Oana Dumitrescu, Jean-Philippe Rasigade, Saskia Lippens, Michelina Plateroti, Elsa Kress, Annabelle Cesaro, Clovis Bondu, Ulrike Rothermel, Mathias Heikenwälder, Gérard Lina, Azzaq Bentaher, Julien Marie, Christophe Caux, Giorgio Trinchieri, Jacqueline Marvel, Marie-Cécile Michallet. PNAS, 24 septembre 2018. DOI : 10.1073/pnas.1722372115